

Marcus Schmitt-Egenolf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4243346/publications.pdf>

Version: 2024-02-01

64
papers

2,253
citations

257357

24
h-index

223716

46
g-index

65
all docs

65
docs citations

65
times ranked

2359
citing authors

#	ARTICLE	IF	CITATIONS
1	Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. <i>Journal of Immunology</i> , 1996, 157, 607-16.	0.4	232
2	Survival, maturation, and function of CD11c- and CD11c+ peripheral blood dendritic cells are differentially regulated by cytokines. <i>Journal of Immunology</i> , 1999, 163, 3250-9.	0.4	175
3	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2461-2498.	1.3	149
4	Genomewide Scan in German Families Reveals Evidence for a Novel Psoriasis-Susceptibility Locus on Chromosome 19p13. <i>American Journal of Human Genetics</i> , 2000, 67, 1020-1024.	2.6	129
5	Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S , which Encode Subcomponents C1r and C1s of Complement. <i>American Journal of Human Genetics</i> , 2016, 99, 1005-1014.	2.6	100
6	Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 583-590.	3.3	99
7	Familial Juvenile Onset Psoriasis Is Associated with the Human Leukocyte Antigen (HLA) Class I side of the Extended Haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: A Population- And Family-Based Study. <i>Journal of Investigative Dermatology</i> , 1996, 106, 711-714.	0.3	95
8	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 281-317.	1.3	84
9	The Higher Proportion of Men with Psoriasis Treated with Biologics May Be Explained by More Severe Disease in Men. <i>PLoS ONE</i> , 2013, 8, e63619.	1.1	82
10	Oligonucleotide Typing Reveals Association of Type I Psoriasis with the HLA-DRB1*0701/2, -DQA* 0201, -DQB1*0303 Extended Haplotype. <i>Journal of Investigative Dermatology</i> , 1993, 100, 749-752.	0.3	71
11	Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis. <i>British Journal of Dermatology</i> , 1997, 136, 147-148.	1.4	65
12	Psoriasis Therapy in Real Life: The Need for Registries. <i>Dermatology</i> , 2006, 213, 327-330.	0.9	56
13	Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. <i>British Journal of Dermatology</i> , 2012, 166, 797-802.	1.4	54
14	National Registries of Systemic Treatment for Psoriasis and the European –Psonet–™ Initiative. <i>Dermatology</i> , 2009, 218, 347-356.	0.9	50
15	PsoReg – The Swedish Registry for Systemic Psoriasis Treatment. <i>Dermatology</i> , 2007, 214, 112-117.	0.9	47
16	Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice. <i>Dermatology</i> , 2012, 225, 326-332.	0.9	45
17	Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies. <i>Dermatology</i> , 2012, 224, 236-243.	0.9	43
18	Anti–TNF treatment during pregnancy and birth outcomes: A population–based study from Denmark, Finland, and Sweden. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 316-327.	0.9	43

#	ARTICLE	IF	CITATIONS
19	Polymorphism in an HLA linked proteasome gene influences phenotypic expression of disease in HLA-B27 positive individuals. <i>Journal of Rheumatology</i> , 1994, 21, 665-9.	1.0	40
20	Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (<scp>PASI</scp>) than with the Dermatology Life Quality Index (<scp>DLQI</scp>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 452-456.	1.3	38
21	EDAR mutation in autosomal dominant hypohidrotic ectodermal dysplasia in two Swedish families. <i>BMC Medical Genetics</i> , 2006, 7, 80.	2.1	29
22	Comparative association analysis reveals that corneodesmosin is more closely associated with psoriasis than HLA-Cw*0602-B*5701 in German families. <i>Tissue Antigens</i> , 2001, 57, 440-446.	1.0	28
23	Prevalence and incidence of generalized pustular psoriasis in Sweden: a population-based register study*. <i>British Journal of Dermatology</i> , 2022, 186, 970-976.	1.4	27
24	Association scan of the novel psoriasis susceptibility region on chromosome 19: evidence for both susceptible and protective loci. <i>Experimental Dermatology</i> , 2003, 12, 490-496.	1.4	26
25	Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals. <i>British Journal of Dermatology</i> , 2020, 182, 965-973.	1.4	26
26	Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis. <i>British Journal of Dermatology</i> , 2003, 149, 381-385.	1.4	25
27	Malignant melanoma: gender patterns in care seeking for suspect marks. <i>Journal of Clinical Nursing</i> , 2011, 20, 2676-2684.	1.4	25
28	Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics. <i>British Journal of Dermatology</i> , 2016, 174, 579-587.	1.4	25
29	Paediatric infections in the first 3 years of life after maternal anti- TNF treatment during pregnancy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 843-854.	1.9	25
30	PERB11 (MIC): a polymorphic MHC gene is expressed in skin and single nucleotide polymorphisms are associated with psoriasis. <i>Clinical and Experimental Immunology</i> , 2000, 119, 553-558.	1.1	22
31	Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study. <i>Dermatology and Therapy</i> , 2021, 11, 2107-2121.	1.4	22
32	Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. <i>British Journal of Dermatology</i> , 2013, 169, 710-714.	1.4	19
33	Analysis of TAP2 and HLA-DP gene polymorphism in Psoriasis. <i>Human Immunology</i> , 1994, 40, 299-302.	1.2	18
34	Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register. <i>British Journal of Dermatology</i> , 2018, 178, 245-252.	1.4	17
35	Promoter Polymorphism at TNF of the Tumor Necrosis Factor Alpha Gene is Not Associated with Early Onset Psoriasis when Tested by the Transmission Disequilibrium Test. <i>Journal of Investigative Dermatology</i> , 1999, 112, 514-515.	0.3	16
36	How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 151.	1.0	16

#	ARTICLE	IF	CITATIONS
37	Patients' decision making in seeking care for suspected malignant melanoma. <i>Journal of Nursing and Healthcare of Chronic Illness</i> , 2010, 2, 164-173.	0.5	15
38	Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study. <i>JAMA Dermatology</i> , 2020, 156, 795.	2.0	15
39	Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients. <i>BioDrugs</i> , 2017, 31, 75-82.	2.2	14
40	Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). <i>Clinical Epidemiology</i> , 2021, Volume 13, 1141-1153.	1.5	13
41	Type I and Type II psoriasis Show a Similar Usage of T-Cell Receptor Variable Regions. <i>Journal of Investigative Dermatology</i> , 1991, 97, 1053-1056.	0.3	12
42	Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden. <i>Acta Dermato-Venereologica</i> , 2015, 95, 156-161.	0.6	12
43	Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice. <i>BioDrugs</i> , 2016, 30, 145-151.	2.2	12
44	Health-Care Delay in Malignant Melanoma: Various Pathways to Diagnosis and Treatment. <i>Dermatology Research and Practice</i> , 2014, 2014, 1-6.	0.3	11
45	Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden. <i>BioDrugs</i> , 2015, 29, 389-398.	2.2	10
46	Coping styles in decision-making among men and women diagnosed with malignant melanoma. <i>Journal of Health Psychology</i> , 2013, 18, 1445-1455.	1.3	9
47	EDAR-induced hypohidrotic ectodermal dysplasia: a clinical study on signs and symptoms in individuals with a heterozygous c.1072C>T mutation. <i>BMC Medical Genetics</i> , 2014, 15, 57.	2.1	9
48	Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent. <i>Dermatology</i> , 2015, 230, 347-353.	0.9	8
49	Prevalence and incidence of palmoplantar pustulosis in Sweden: a population-based register study*. <i>British Journal of Dermatology</i> , 2021, 185, 945-951.	1.4	8
50	Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study. <i>Psoriasis: Targets and Therapy</i> , 2022, Volume 12, 89-98.	1.2	8
51	Physical activity and lifestyle improvement in the management of psoriasis. <i>British Journal of Dermatology</i> , 2016, 175, 452-453.	1.4	7
52	Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥ 10 and/or DLQI ≥ 10 under ongoing systemic therapy. <i>Journal of Dermatological Treatment</i> , 2017, 28, 500-504.	1.1	7
53	Hair shaft structures in EDAR induced ectodermal dysplasia. <i>BMC Medical Genetics</i> , 2015, 16, 79.	2.1	5
54	Association and Linkage of Human Leukocyte Antigens with Psoriasis – Revisited. <i>Transfusion Medicine and Hemotherapy</i> , 2002, 29, 326-330.	0.7	4

#	ARTICLE	IF	CITATIONS
55	Complete skin clearance and beyond. British Journal of Dermatology, 2021, 184, 3-4.	1.4	3
56	Switching Biologicals: Switching TNF± Antagonists in Psoriasis Treatment. Dermatology, 2008, 216, 281-282.	0.9	2
57	Health-related quality of life in patients with melanoma – characterization of a Swedish cohort. British Journal of Dermatology, 2020, 182, 506-508.	1.4	2
58	The Relationship Between Disease Severity and Quality of Life In Patients With Moderate to Severe Psoriasis. Value in Health, 2015, 18, A675.	0.1	1
59	Patient Registries for Safety. Methods in Pharmacology and Toxicology, 2018, , 149-164.	0.1	1
60	Perception of information to Swedish melanoma patients in routine clinical practice – a cross-sectional survey. BMC Cancer, 2022, 22, 159.	1.1	1
61	What can we learn from “dropouts” in clinical trials?. British Journal of Dermatology, 2018, 178, 318-319.	1.4	0
62	ä1/2;ç””ç”ÿç%o©ç--æ³•æ²»ç--é“¶á±‘ç—...çš,,æCEç»·PASIã€DLQI áš EQã€5D ç»“æžœ:áÿ°ã°Žç‘žã...ã1/2ã®¶é“¶á±‘ç4...ç™»ð°çš,,ãá1ç		
63	Severity of psoriasis – Time to disentangle severity from symptom control. British Journal of Dermatology, 2022, , .	1.4	0
64	Diverse research designs are needed for population health: Lessons from Maslow. Lifestyle Medicine, 2022, 3, .	0.3	0